BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer

The study evaluated the efficacy and safety of the BRAF inhibitor dabrafenib in 14 patients with metastatic BRAF-mutant thyroid cancer. Dabrafenib demonstrated promising antitumor activity, with a 29% response rate and 64% of patients experiencing at least a 10% reduction in tumor size. The median progression-free survival was 11.3 months. The treatment was well tolerated, with mostly mild side effects such as skin papillomas, hyperkeratosis, and alopecia. The study concluded that dabrafenib is a promising treatment for BRAF-mutant differentiated thyroid cancer, warranting further research to confirm these results and explore its long-term benefits and potential side effects.